Page 172 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 5
other anticancer drugs (excluding the FOLFOX regimen); 5-FU + RT: 5-fluorouracil combined with radiotherapy (with or without mitomycin); BC: breast cancer; BSA: body surface area; CAP mono: capecitabine monotherapy (with or without bevacizumab); CAPOX: capecitabine combined with oxaliplatin (with or without bevacizumab); CAP other: capecitabine combined with other anticancer drugs; CAP + RT: capecitabine combined with radiotherapy (with or without mitomycin); CRC: colorectal cancer; DPYD: gene encoding dihydropyrimidine dehydrogenase; FOLFOX: 5-fluorouracil combined with oxaliplatin and leucovorin (with or without bevacizumab); GC: gastric cancer; IQR: interquartile range; NS: not specified.
Supplementary Table 2. Incidences of severe toxicity in DPYD variant allele carriers in this study and the historical cohort
DPYD variant
c.1236G>A c.2846A>T DPYD*2A c.1679T>G
DPYD variant carriers treated with reduced dose
(this study)
N of patients with overall grade ≥3 toxicity / total N of patients with this variant (%)
20 / 51 (39%) 8 / 17 (47%) 5 / 16 (31%) 0 / 1 (0%)
DPYD variant carriers treated with full dose
(meta-analysis)
N of patients with overall grade ≥3 toxicity / total N of patients with this variant (%)
65 / 177 (37%) 53 / 85 (62%) 43 / 60 (72%) 6 / 11 (55%)
170